Acadia’s Nuplazid Shows Nearly Three-Fold Reduction In Psychosis Relapse
Executive Summary
Data presented at the CTAD meeting for pimavanserin in dementia-related psychosis will support an sNDA filing in 2020 for an approval that could broaden the drug’s market exponentially.
You may also be interested in...
Acadia's Nuplazid Hits A Review Roadblock, But Not A CRL (For Now)
Deficiencies identified by the US FDA could delay the approval of pimavanserin for hallucinations associated with dementia-related psychosis, but Acadia did not have details for investors.
Keeping Track: Keytruda Claims First TMB-Based Cancer Indication; TG Therapeutics Submits First Umbralisib NDA
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Acadia Revives Nuplazid’s Chances In Schizophrenia With Negative Symptom Data
After a Phase III failure in refractory schizophrenia, Acadia has Phase II data showing efficacy in negative symptoms of the disease, an unmet need. It plans a pivotal study in 2020.